Less Ads, More Data, More Tools Register for FREE

Pin to quick picksASLR.L Regulatory News (ASLR)

  • There is currently no data for ASLR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update re: Dev Clever Subscription Rights

27 Jan 2021 07:00

RNS Number : 9786M
Asimilar Group PLC
27 January 2021
 

The information contained in this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014). Upon publication of the announcement via a regulatory information service, this information is considered to be in the public domain.

27 January 2021

 

 

ASIMILAR GROUP PLC ('ASIMILAR' OR 'THE COMPANY')

 

Update re: Dev Clever Subscription Rights

 

Asimilar Group plc (AIM: ASLR), the AIM quoted investment company focused on technology opportunities in the fields of big data, machine learning, telematics and the Internet of Things (IoT), announces that, further to the announcements on 2 November 2020 and 1 December 2020, its wholly owned subsidiary, Intrinsic Capital (Jersey) Limited ("ICJL"), has agreed with Dev Clever Holdings plc ("Dev Clever") to revise the terms of the subscription rights held by ICJL to invest in new ordinary shares in Dev Clever at 10 pence per share ("Subscription Rights") as follows:

 

§ the longstop date of 30 June 2021 for the fourth investment tranche has been brought forward to 28 February 2021 to coincide with the long-stop date of the third investment tranche giving ICJL the right to subscribe to up to 60,000,000 ordinary shares in Dev Clever at a price of 10p per share, for a consideration of up to £6 million, by no later than 28 February 2021, subject to the publication by Dev Clever of a prospectus approved by the FCA no later than 28 February 2021, failing which the Subscription Rights will lapse.

§ Under the revised arrangements, Dev Clever and ICJL have also agreed to vary ICJL's right to receive a warrant to subscribe for 50 million ordinary shares of Dev Clever at 25 pence per share ("Warrant"), such that the Warrant may be exercised in full or in part (each time in respect of at least 10 million new ordinary shares of Dev Clever) for a period of 2 years (rather than 3 years as per the original agreement) from the later of (a) completion of subscription by ICJL for the second investment tranche (as announced on 26 January 2021); or (b) the date of the grant of the Warrant. The Warrant will be granted conditional upon Dev Clever shareholders having given authority to issue and allot all of the Warrant shares on a non pre-emptive basis. For the avoidance of doubt neither the grant of the Warrant nor its exercise will be conditional on subscription by ICJL for any further subscription tranches (other than the second tranche). The remaining provisions of the Warrant agreement remain unchanged. 

 

-Ends-

Contacts

Asimilar Group plc

John Taylor, Non-Executive Chairman

via Buchanan

Cairn Financial Advisers LLP

Sandy Jamieson / Liam Murray

Tel: +44 20 7213 0880

Peterhouse Capital Limited

Duncan Vasey / Lucy Williams

Tel: + 44 20 7220 9797

Buchanan Communications Limited

Richard Oldworth / Chris Lane

Tel: +44 (0) 20 7466 5000

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEAPFKADNFEFA
Date   Source Headline
23rd Jun 20087:00 amRNSInterim Results
9th Jun 200812:00 pmRNSContract Win
19th Mar 20082:29 pmRNSDirector/PDMR Shareholding
17th Mar 20082:22 pmRNSPosting of annual report
29th Feb 20087:01 amRNSContract gains
27th Feb 20089:27 amRNSHolding(s) in Company
26th Feb 20081:58 pmRNSDirector/PDMR Shareholding
25th Feb 20082:21 pmRNSAGM Statement
6th Feb 20087:01 amRNSAdditional Listing & Placing
31st Jan 20083:35 pmRNSFinal Results
6th Nov 20075:40 pmRNSDirectorate Change
15th Oct 20077:00 amRNSBlue chips trial product
8th Oct 20077:01 amRNSSignificant contract gain
28th Sep 20077:02 amRNSContract Gains
21st Sep 20077:01 amRNSSignificant contract gain
10th Sep 20077:02 amRNSPrivate Placing
17th Aug 20079:07 amRNSRule 26 compliance
13th Aug 20077:00 amRNSContract gains
6th Aug 20077:00 amRNSNew distributor
29th Jun 20077:01 amRNSInterim Results
22nd Jun 20077:01 amRNSContract gains
15th Jun 20077:01 amRNSContract gain
23rd May 20077:01 amRNSBoard Change
14th May 200711:22 amRNSAGM Statement
11th May 20077:01 amRNSNew product launch
23rd Apr 20077:02 amRNSAppointment of Distributors
20th Apr 20075:47 pmRNSDirector/PDMR Shareholding
19th Apr 20077:01 amRNSContract gain
4th Apr 20077:03 amRNSGrowing presence in the USA
29th Mar 200712:15 pmRNSFinal Results
19th Jan 200711:29 amRNSTotal Voting Rights
22nd Dec 200610:06 amRNSTotal Voting Rights
6th Dec 20066:41 pmRNSIssue of Equity
10th Nov 20067:00 amRNSRe Contract
3rd Nov 20067:00 amRNSRe Contract
27th Oct 20067:01 amRNSRe Contract
26th Sep 20061:10 pmRNSIssue of Equity
22nd Sep 20067:00 amRNSContract wins
31st Jul 20067:00 amRNSContract gain
24th Jul 20067:01 amRNSInvestment
15th Jun 20063:05 pmRNSIssue of Equity
14th Jun 20067:01 amRNSInterim Results
6th Jun 20067:01 amRNSContract gain
15th May 200611:37 amRNSDisposal
18th Apr 20067:01 amRNSBoard changes
31st Mar 20063:36 pmRNSAnnual Report and Accounts
31st Mar 200610:37 amRNSFinal Results
24th Feb 20067:00 amRNSCompany Restructure
8th Dec 20057:00 amRNSBahrain office & contract win
25th Nov 20057:00 amRNSBoard Appointment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.